Background: This subgroup analysis of the RE-ENACT study evaluates the effectiveness of Razumab ® (the world's first biosimilar of ranibizumab by Intas Pharmaceuticals Ltd.) in Indian patients with retinal vein occlusion (RVO). Methods: The data on patients with RVO who had received ≥3 injections of Razumab ® between January and August 2016 were analyzed. Endpoints were: improvement in best corrected visual acuity (BCVA), and a decrease in central macular thickness (CMT), intraretinal fluid (IRF), and subretinal fluid (SRF) from baseline at weeks 4, 8, and 12. Results: Of 160 patients, the majority (61.87%) were men. The mean (±SE) BCVA improved from baseline (0.76 ± 0.04) to week 4 (0.73 ± 0.03; p = 0.0656), which attained significance at week 8 (0.55 ± 0.02; p < 0.0001) and week 12 (0.47 ± 0.02; p < 0.0001). The mean (±SE) CMT significantly decreased from baseline (447.60 ± 10.91 μm) to week 4 (431.84 ± 10.92 μm; p = 0.0028), week 8 (339.28 ± 8.12 μm; p < 0.0001), and week 12 (298.23 ± 6.68 μm; p < 0.0001). The proportion of patients with IRF and SRF significantly (p < 0.0001) decreased from baseline to weeks 4, 8, and 12 (IRF: from 70.63 to 45.63, 39.38, and 30.00%, respectively; SRF: from 65.63 to 37.50, 28.13, and 24.38%, respectively). A subgroup analysis of branch RVO and central RVO showed similar results. No new safety concerns were observed. Conclusion: Razumab ® (biosimilar of ranibizumab) effectively improved visual acuity and disease outcomes in patients with RVO in a real-world setting with no new safety concerns.
Introduction
Retinal vein occlusion (RVO), the second most common cause of retinal vascular disease after diabetic retinopathy, is a significant cause of unilateral and painless loss of vision [1] [2] [3] . Based on the localization of venous
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occlusion, the most frequently occurring types are branch RVO (BRVO), defined as occlusion of a branch of the retinal vein system, and central RVO (CRVO), defined as occlusion located in the central retinal vein [4, 5] .
RVO is a significant cause of vision loss with an overall incidence of 0.21% among patients aged ≥40 years [6] . The prevalence of RVO varies from 0.7 to 1.6% [7] . An estimated 16 million people globally develop RVO, with BRVO comprising 80% of cases [8] . BRVO is more common than CRVO [9] , and may result in intraocular inflammatory changes; it affects approximately 1% of the population. The estimated prevalence of BRVO ranges from 0.6 to 1.1% [10] . It can cause severe vision loss through macular edema, retinal neovascularization, and retinal detachment [11] . Arterial stiffness is the main pathogenic mechanism for the development of BRVO, which can cause venous compression in the common adventitial sheath [4, 7] . Increasing age, concomitant cardiovascular diseases, smoking, and hypertension are the major risk factors for BRVO [12] .
Treatment options for managing macular edema with RVO include macular grid laser photocoagulation and anti-vascular endothelial growth factor (VEGF) inhibitors. The treatment of retinal vascular diseases, including RVO, has been revolutionized with the introduction of intravitreal pharmacotherapy. Anti-VEGF therapy has now become the treatment of choice for macular edema secondary to RVO. Several multicenter studies have shown that anti-VEGF treatment is effective in reducing intraretinal fluid (IRF) and retinal hemorrhages, associated with a statistically significant improvement in visual acuity [13] [14] [15] . Ranibizumab, dexamethasone implants, off-label bevacizumab, and triamcinolone have demonstrated efficacy in the therapy of macular edema secondary to RVO and significantly expanded treatment options, becoming the standard of care [14] [15] [16] [17] .
In the pathological process of RVO, VEGF plays a crucial role, with upregulated expression by hypoxia and a number of other stimuli. In RVO patients, the VEGF concentration in the ocular fluid is increased, which correlates with the severity of macular edema [5, [18] [19] [20] . Several anti-VEGF agents have been widely used for treating macular edema secondary to RVO, including ranibizumab. Ranibizumab binds to and inhibits VEGF, a key driver of macular edema in RVO. The efficacy of intravitreal ranibizumab for treating macular edema in patients with RVO has been established in several studies [15, [21] [22] [23] . The pivotal phase III BRAVO [23] (Branch Retinal Vein Occlusion) and CRUISE [24] (Central Retinal Vein Occlusion) studies facilitated the approval of ranibizumab for the treatment of visual impairment due to macular edema secondary to RVO.
Ranibizumab has been approved in the USA (2010) and the European Union (2011) for the treatment of visual impairment due to macular edema secondary to RVO. Razumab ® (the world's first biosimilar of ranibizumab by Intas Pharmaceuticals Ltd.) was approved by the Drug Controller General of India in February 2015 for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), macular edema following RVO, and visual impairment due to choroidal neovascularization secondary to pathological myopia.
The efficacy and safety of ranibizumab in the treatment of RVO has been established in several prospective, randomized, double-masked clinical trials. The efficacy and tolerability of Razumab ® has been demonstrated in a prospective study in Indian patients with chorioretinal vascular diseases including RVO [25] . However, these studies are done in a controlled clinical environment and may not reflect data from an actual clinical setting. Hence, a retrospective data collection study (RE-ENACT) was conducted to collect the data and analyze the effectiveness of the ranibizumab biosimilar in a "real-world" setting among patients with wet AMD, DME, and RVO. A subgroup analysis of the wet AMD population was published elsewhere [26] . This report presents a subgroup analysis regarding the effectiveness of Razumab ® in Indian patients with RVO in routine clinical settings.
Subjects and Methods

Study Population
This subgroup analysis included patients with RVO of either sex aged ≥18 years who had received ≥3 ranibizumab biosimilar injections between January and August 2016 as part of their routine clinical care.
Study Design
This is a subgroup analysis of the patients with RVO from the RE-ENACT study, which was a retrospective, multicenter, organized observational study that analyzed the medical charts of patients who had been administered ≥3 intravitreal ranibizumab biosimilar injections (4-weekly) between January 2016 and August 2016 at 16 centers in India.
Both treatment-naïve patients and patients treated with other anti-VEGF/steroids/laser treatment were included in the study. Patients with dense cataracts were excluded where optical coherence tomography (OCT) assessment was not possible.
Study Assessments
The primary endpoints were the mean change in best corrected visual acuity (BCVA), measured by Snellen's chart or the logMAR 
Statistical Analysis
Demographic and baseline characteristics were summarized using descriptive statistics. Categorical variables were summarized by frequency and percentage. Continuous variables were summarized by count, mean, standard deviation, median, and minimum and maximum. BCVA and CMT data were analyzed using twotailed paired t tests. IRF and SRF data were analyzed using the χ 2 test. Mean percent changes in BCVA and CMT were calculated as an average value of percent change from baseline to a particular visit. All statistical analyses were done using SAS 9.3 or higher.
Results
Patients' Disposition and Demographics
This subgroup analysis included 160 patients (99 men and 61 women) with RVO who had received ≥3 intravitreal ranibizumab biosimilar injections (4-weekly) between January 2016 and August 2016. BRVO (55%) was the commonest type, followed by CRVO (35%) and hemi-RVO (HRVO) (1.25%); details on 14 patients (8.75%) were not available. Diabetes (52.4%; 84/160) and hypertension (60.6%; 97/160) were the most common comorbidities found in these patients. The baseline characteristics of the patients are summarized in Table 1 .
Endpoints
Best Corrected Visual Acuity The mean (±SE) pretreatment logMAR BCVA was 0.76 ± 0.04. By week 4, the mean BCVA demonstrated an improvement to 0.73 ± 0.03 after the administration of a ranibizumab biosimilar injection (p = 0.0656). The im- (Fig. 3) .
Subgroup Analysis for BRVO and CRVO
Best Corrected Visual Acuity The mean (±SE) logMAR BCVA in the BRVO subgroup changed from baseline (0.69 ± 0.04) to week 4 (0.70 ± 0.04, p = 0.75), but was statistically nonsignificant; however, it showed statistically significant improvements thereafter at week 8 (0.51 ± 0.02) and week 12 (0.43 ± 0.02; p < 0.001 for both time points). In the CRVO subgroup, the mean (±SE) logMAR BCVA improved from baseline (0.84 ± 0.07) to week 4 (0.81 ± 0.06, p = 0.33), but was also statistically nonsignificant; the improvement again attained significance by week 8 (0.61 ± 0.03), which was sustained till week 12 (0.52 ± 0.02; p < 0.001 for both time points) (Fig. 4) . In the HRVO subgroup, the mean (±SE) logMAR BCVA showed continuous improvement from baseline (0.63 ± 22.87) to week 4 (0.54 ± 22.19), week 8 (0.39 ± 9.23), and week 12 (0.39 ± 7.79). Central Macular Thickness The mean (±SE) CMT in the BRVO subgroup improved from baseline (441.38 ± 12.33 μm) to week 4 (434.78 ± 12.01 μm, p = 0.20), but was statistically nonsignificant; however, it showed a statistically significant improvement thereafter at week 8 (342.28 ± 12.99 μm) and week 12 (297.47 ± 10.91 μm; p < 0.001 for both time points). In the CRVO subgroup, the mean (±SE) CMT improved from baseline (451.09 ± 0.15 μm) to week 4 (447.50 ± 0.24 μm, p = 0.32), but again was statistically nonsignificant; it again showed a statistically significant improvement thereafter at week 8 (341.32 ± 0.21 μm) and week 12 (303.89 ± 0.21 μm; p < 0.001 for both time points) (Fig. 5) . In the HRVO subgroup, the mean (±SE) CMT showed continuous improvement from baseline (647.5 ± 82.5 μm) to week 4 (571 ± 159 μm), week 8 (394 ± 66 μm), and week 12 (282.5 ± 17.5 μm).
Intraretinal and Subretinal Fluid
In the BRVO subgroup, a significant (p < 0.05) reduction in the proportion of patients having IRF or SRF from baseline to weeks 4, 8 (Fig. 6 ). In the HRVO subgroup, the proportion of patients having IRF or SRF decreased from baseline to week 12 (IRF: from 100 to 50%; SRF: from 100 to 0%).
Discussion
This retrospective subgroup analysis of the RE-EN-ACT study, which analyzed the pooled data on patients with wet AMD, DME, and RVO, sought to investigate the "real-world" clinical use of a ranibizumab biosimilar from Intas Pharmaceuticals Ltd., India. The subgroup analyses reported the effectiveness of the ranibizumab biosimilar in the treatment of patients with RVO. The results showed that BCVA and CMT improved from baseline, indicating an improvement in visual acuity and disease condition after the first injection of the ranibizumab biosimilar (week 4), which was maintained after the administration of the third injection at week 12. Furthermore, improvements in SRF and IRF were also seen at all time points. The findings from the present study on the ranibizumab biosimilar are consistent with those from several studies that demonstrate the effectiveness of ranibizumab in patients with RVO.
The efficacy and safety of ranibizumab in the treatment of macular edema in patients with RVO by improving visual function, IRF, and SRF have been established in several studies [15, [21] [22] [23] . Ranibizumab not only prevents vision loss but also improves visual acuity [27] [28] [29] . It has significantly improved visual function and reduced IRF and SRF [30] . The current subgroup analysis, which evaluated data for a duration of 3 months, demonstrated marked improvements in BCVA, CMT, IRF, and SRF as early as at the 4-week follow-up, with lasting benefits till the 12-week follow-up. A significant improvement in BCVA was reported in the pivotal BRAVO and CRUISE studies with ranibizumab treatment in patients with RVO, which was sustained over 12 months [15, 18, 23] . In our study, a significant improvement in logMAR BCVA was observed starting at week 4 and lasting over 12 weeks after ranibizumab biosimilar therapy; this is consistent with the results from the original pooled data as well as from several reported studies [31, 32] . Ranibizumab was associated with improved BCVA till 6 months in macular edema after BRVO in a prospective observational study, suggesting a positive correlation of the short-term effects of ranibizumab with long-term improvements [8] . Another study, conducted by Chui and Petrunya [33] , showed that a significant improvement in visual function and a persistent reduction in macular edema secondary to BRVO is achieved after 1 ranibizumab biosimilar injection per month over a 3-month period.
Ganglion cell damage is associated with the thickness of the central macula. A very thin or thick retina, thick subretinal tissue, atrophy, and scarring are associated with worse visual acuity [34] . Ganglion cell damage results from traction to the ganglion cell due to a greater CMT. A decrease in CMT with a concomitant increase in visual acuity is warranted by pharmacological treatment [34, 35] . The current study demonstrated a significant decrease in CMT with ranibizumab biosimilar treatment, indicating improved disease outcomes and reflecting the results from the original pooled analysis. Similar results have been shown for ranibizumab, with a significant reduction in CMT as early as at week 4 and lasting over 3 months after the injection in a study involving 32 patients [36] . Another retrospective, observational, multicenter (n = 200) study showed a significant decrease in CMT at 6 months after ranibizumab treatment [37] . Similarly, a significant reduction in CMT was observed in BRVO (n = 21) and CRVO (n = 10) patients after ranibizumab treatment [38] . Overall, the subgroup analysis demonstrates effects of the ranibizumab biosimilar in functional and anatomical visual improvements in BCVA and CMT, and the degree of improvement was similar to that reported in several studies with ranibizumab administration.
RVO generally presents with an accumulation of IRF and SRF [39] . Ranibizumab has been shown to decrease IRF and SRF in RVO patients. Bhisitkul et al. [40] reported resolution of SRF in almost all patients with RVO 3 months after ranibizumab treatment. The long-term CRYSTAL study demonstrated that ranibizumab treatment effectively reduced the proportion of patients with SRF by 24 months [41] . The BRIGHTER study reported a decreased proportion of patients with visible IRF and SRF 6 months after ranibizumab treatment [42] . Similar results were also observed in the current subgroup analysis, which showed a significant decrease in the proportion of patients with IRF or SRF after ranibizumab biosimilar treatment, again consistent with the original pooled analysis.
Improvements in BCVA, CMT, IRF, and SRF were observed for the entire population of this study, which were similar for the BRVO and CRVO subgroups. The probable reasons for the statistically nonsignificant changes in mean logMAR BCVA in the BRVO subgroup from baseline to week 4 could be factors like the severity and duration of the disease, poor patient compliance, tachyphylaxis (in patients previously treated with other anti-VEGF agents), and uncontrolled comorbid conditions at baseline. Tachyphylaxis can occur during treatment with ranibizumab or any anti-VEGF agent [43] . The precise mechanism of the development of tachyphylaxis is unclear. Both local and systemic factors might be involved. These BRVO and CRVO subgroup results showed improvements in the efficacy parameters for ranibizumab, similar to the data reported by Sakanishi et al. [38] .
The RE-ENACT study -that is, the original retrospective pooled study -did not capture the complete information on adverse events in the medical records, and, hence, they were not analyzed in this subgroup. Overall, no new safety concerns compared to the innovator product were observed.
Conclusions
From the pooled RE-ENACT study, which was a retrospective, observational study on wet AMD, DME, and RVO, the current subgroup analysis of patients with RVO showed that intravitreal injection of Razumab ® , the world's first biosimilar of ranibizumab by Intas Pharmaceuticals Ltd., is effective in reducing macular thickness and improving visual acuity in the real-world setting. 
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